Sustained drug release in nanomedicine: A long-acting nanocarrier-based formulation for glaucoma

ACS Nano

Volumn 8, Issue 1, 2014, Pages 419-429

  Natarajan, Jayaganesh V ^a   Darwitan, Anastasia ^a   Barathi, Veluchamy A ^b   Ang, Marcus ^c   Htoon, Hla Myint ^b   Boey, Freddy ^a   Tam, Kam C ^d   Wong, Tina T ^a,b,c   Venkatraman, Subbu S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

drug liposomal interactions; glaucoma; nanocarrier; nanomedicine; sustained drug delivery

Indexed keywords

ANTI-CANCER THERAPIES; BIOACTIVE MOLECULES; GLAUCOMA; INTRA OCULAR PRESSURE; ISOTHERMAL TITRATION CALORIMETRY; NANOCARRIERS; SUSTAINED DRUG RELEASE; UNILAMELLAR VESICLE;

DRUG DELIVERY; DRUG PRODUCTS; ENZYME INHIBITION; LIPOSOMES; MEDICAL NANOTECHNOLOGY; OPHTHALMOLOGY;

LOADING;

DRUG CARRIER;

ANIMAL; ARTICLE; CALORIMETRY; DELAYED RELEASE FORMULATION; GLAUCOMA; MACACA FASCICULARIS; MEDICINAL CHEMISTRY; NANOMEDICINE;

ANIMALS; CALORIMETRY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GLAUCOMA; MACACA FASCICULARIS; NANOMEDICINE;

EID: 84893450875     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn4046024     Document Type: Article

References (43)

1. Farokhzad, O. C.; Langer, R. Impact of Nanotechnology on Drug Delivery ACS Nano 2009, 3, 16-20
2. Duncan, R.; Gaspar, R. Nanomedicine(s) under the Microscope Mol. Pharmaceutics 2011, 8, 2101-2141
3. Wagner, V.; Dullaart, A.; Bock, A. K.; Zweck, A. The Emerging Nanomedicine Landscape Nat. Biotechnol. 2006, 24, 1211-1217
4. Vasir, J. K.; Labhasetwar, V. Biodegradable Nanoparticles for Cytosolic Delivery of Therapeutics Adv. Drug Delivery Rev. 2007, 59, 718-728
5. Allen, T. M.; Cullis, P. R. Liposomal Drug Delivery Systems: From Concept to Clinical Applications Adv. Drug Delivery Rev. 2013, 65, 36-48
6. Torchilin, V. P. Micellar Nanocarriers: Pharmaceutical Perspectives Pharm. Res. 2007, 24, 1-16
7. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric Drugs for Efficient Tumor-Targeted Drug Delivery Based on EPR-Effect Eur. J. Pharm. Biopharm. 2009, 71, 409-419
8. Haran, G.; Cohen, R.; Bar, L. K.; Barenholz, Y. Transmembrane Ammonium-Sulfate Gradients in Liposomes Produce Efficient and Stable Entrapment of Amphiphatic Weak Bases Biochim. Biophys. Acta, Biomembr. 1993, 1151, 201-215
9. Chang, H. I.; Yeh, M. K. Clinical Development of Liposome-Based Drugs: Formulation, Characterization, and Therapeutic Efficacy Int. J. Nanomed. 2012, 7, 49-60
10. Quigley, H. A.; Broman, A. T. The Number of People with Glaucoma Worldwide in 2010 and 2020 Br. J. Ophthalmol. 2006, 90, 262-267
11. Gooch, N.; Molokhia, S. A.; Condie, R.; Burr, R. M.; Archer, B.; Ambati, B. K.; Wirostko, B. Ocular Drug Delivery for Glaucoma Management Pharmaceutics 2012, 4, 197-211
12. Maurice, D.; Mishima, S. Ocular Pharmacokinectis. In Handbook of Experimental Pharmacology; Sears, M. L., Ed.; Springer: Berlin, Germany, 1984; pp 16-119.
13. Tsai, T.; Robin, A. L.; Smith, J. P., 3rd. An Evaluation of How Glaucoma Patients Use Topical Medications: A Pilot Study Trans. Am. Ophthalmol. Soc. 2007, 105, 29-33
14. Nordstrom, B. L.; Friedman, D. S.; Mozaffari, E.; Quigley, H. A.; Walker, A. M. Persistence and Adherence with Topical Glaucoma Therapy Am. J. Ophthalmol. 2005, 140, 598-606
15. Natarajan, J. V.; Ang, M.; Darwitan, A.; Chattopadhyay, S.; Wong, T. T.; Venkatraman, S. S. Nanomedicine for Glaucoma: Liposomes Provide Sustained Release of Latanoprost in the Eye Int. J. Nanomed. 2012, 7
16. Barenholz, Y. Doxil®-The First FDA-Approved Nano-Drug: Lessons Learned J. Controlled Release 2012, 160, 117-134
17. Atyabi, F.; Farkhondehfai, A.; Esmaeili, F.; Dinarvand, R. Preparation of Pegylated Nano-Liposomal Formulation Containing SN-38: In Vitro Characterization and in Vivo Biodistribution in Mice Acta Pharm. 2009, 59, 133-144
18. Bhardwaj, U.; Burgess, D. J. Physicochemical Properties of Extruded and Non-Extruded Liposomes Containing the Hydrophobic Drug Dexamethasone Int. J. Pharm. 2010, 388, 181-189
19. Kim, C. K.; Park, D. K. Stability and Drug Release Properties of Liposomes Containing Cytarabine as a Drug Carrier Arch. Pharmacal Res. 1987, 10, 75-79
20. Drummond, D. C.; Meyer, O.; Hong, K. L.; Kirpotin, D. B.; Papahadjopoulos, D. Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev. 1999, 51, 691-743
21. Charrois, G. J. R.; Allen, T. M. Drug Release Rate Influences the Pharmacokinetics, Biodistribution, Therapeutic Activity, and Toxicity of Pegylated Liposomal Doxorubicin Formulations in Murine Breast Cancer Biochim. Biophys. Acta, Biomembr. 2004, 1663, 167-177
22. Johnston, M. J.; Edwards, K.; Karlsson, G.; Cullis, P. R. Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations J. Liposome Res. 2008, 18, 145-157
23. Johnston, M. J.; Semple, S. C.; Klimuk, S. K.; Edwards, K.; Eisenhardt, M. L.; Leng, E. C.; Karlsson, G.; Yanko, D.; Cullis, P. R. Therapeutically Optimized Rates of Drug Release Can be Achieved by Varying the Drug-to-Lipid Ratio in Liposomal Vincristine Formulations Biochim. Biophys. Acta, Biomembr. 2006, 1758, 55-64
24. Zhigaltsev, I. V.; Maurer, N.; Akhong, Q. F.; Leone, R.; Leng, E.; Wang, J.; Semple, S. C.; Cullis, P. R. Liposome-Encapsulated Vincristine, Vinblastine and Vinorelbine: A Comparative Study of Drug Loading and Retention J. Controlled Release 2005, 104, 103-111
25. Liu, J. B.; Lee, H.; Huesca, M.; Young, A. P.; Allen, C. Liposome Formulation of a Novel Hydrophobic Aryl-Imidazole Compound for Anti-Cancer Therapy Cancer Chemother. Pharmacol. 2006, 58, 306-318
26. Pandelidou, M.; Dimas, K.; Georgopoulos, A.; Hatziantoniou, S.; Demetzos, C. Preparation and Characterization of Lyophilised Egg PC Liposomes Incorporating Curcumin and Evaluation of Its Activity Against Colorectal Cancer Cell Lines J. Nanosci. Nanotechnol. 2011, 11, 1259-1266
27. Kan, P.; Tsao, C. W.; Wang, A. J.; Su, W. C.; Liang, H. F. A Liposomal Formulation Able to Incorporate a High Content of Paclitaxel and Exert Promising Anticancer Effect J. Drug Delivery 2011, 2011, 629234
28. Khan, D. R.; Rezler, E. M.; Lauer-Fields, J.; Fields, G. B. Effects of Drug Hydrophobicity on Liposomal Stability Chem. Biol. Drug Des. 2008, 71, 3-7
29. Bernsdorff, C.; Reszka, R.; Winter, R. Interaction of the Anticancer Agent Taxol (TM) (paclitaxel) with Phospholipid Bilayers J. Biomed. Mater. Res. 1999, 46, 141-149
30. Kawasaki, Y.; Freire, E. Finding a Better Path to Drug Selectivity Drug Discovery Today 2011, 16, 985-990
31. DeRuiter, J. Prostaglandins and the Eicosanoids Principles Drug Action 2002, 1-28
32. Kawasaki, Y.; Chufan, E. E.; Lafont, V.; Hidaka, K.; Kiso, Y.; Mario Amzel, L.; Freire, E. How Much Binding Affinity Can Be Gained by Filling a Cavity? Chem. Biol. Drug Des. 2010, 75, 143-151
33. Lafont, V.; Armstrong, A. A.; Ohtaka, H.; Kiso, Y.; Mario Amzel, L.; Freire, E. Compensating Enthalpic and Entropic Changes Hinder Binding Affinity Optimization Chem. Biol. Drug Des. 2007, 69, 413-422
34. Wu, G. H.; Lee, K. Y. C. Interaction of Poloxamers with Liposomes: An Isothermal Titration Calorimetry Study J. Phys. Chem. B 2009, 113, 15522-15531
35. Trandum, C.; Westh, P.; Jorgensen, K.; Mouritsen, O. G. Association of Ethanol with Lipid Membranes Containing Cholesterol, Sphingomyelin and Ganglioside: a Titration Calorimetry Study Biochim. Biophys. Acta, Biomembr. 1999, 1420, 179-188
36. Ikonen, M.; Murtomaki, L.; Kontturi, K. Microcalorimetric and Zeta Potential Study on Binding of Drugs on Liposomes Colloids Surf., B 2010, 78, 275-282
37. Manrique-Moreno, M.; Howe, J.; Suwalsky, M.; Garidel, P.; Brandenburg, K. Physicochemical Interaction Study of Non-Steroidal Anti-Inflammatory Drugs with Dimyristoylphosphatidylethanolamine Liposomes Lett. Drug Des. Discovery 2010, 7, 50-56
38. Nomura, S.; Hashimoto, M. Pharmacological Profiles of Latanoprost (Xalatan), a Novel Anti-Glaucoma Drug Nihon Yakurigaku Zasshi. 2000, 115, 280-286
39. Stjernschantz, J. W. From PGF(2 alpha)-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan-The Proctor Lecture Invest. Ophthalmol. Visual Sci. 2001, 42, 1134-1145
40. Schumer, R. A.; Camras, C. B.; Mandahl, A. K. Latanoprost and Cystoid Macular Edema: Is There a Causal Relation? Curr. Opin. Ophthalmol. 2000, 11, 94-100
41. Moon, J. W.; Song, Y. K.; Jee, J. P.; Kim, C. K.; Choung, H. K.; Hwang, J. M. Effect of Subconjunctivally Injected, Liposome-Bound, Low-Molecular-Weight Heparin on the Absorption Rate of Subconjunctival Hemorrhage in Rabbits Invest. Ophthalmol. Visual Sci. 2006, 47, 3968-3974
42. Seelig, J. Thermodynamics of Lipid-Peptide Interactions Biochim. Biophys. Acta, Biomembr. 2004, 1666, 40-50
43. Kumaran, S.; Jez, J. M. Thermodynamics of the Interaction between O-Acetylserine Sulfhydrylase and the C-Terminus of Serine Acetyltransferase Biochemistry 2007, 46, 5586-5594